The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue

European Journal of Pharmacology

Volumn 620, Issue 1-3, 2009, Pages 78-83

  Gonçalves, Roberta L ^a   Lugnier, Claire ^b   Keravis, Thérèse ^b   Lopes, Miguel J ^a   Fantini, Fernando A ^c   Schmitt, Martine ^b   Cortes, Steyner F ^a   Lemos, Virginia S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Faculté de Pharmacie   (France)

^c Biocor Instituto   (Brazil)

Author keywords

8 methoxymethyl IBMX; Endothelium; H 89; Human saphenous vein; Rp 8 pCPT cGMPS; Vinpocetine

Indexed keywords

3 ISOBUTYL 8 METHOXYMETHYL 1 METHYLXANTHINE; CALMODULIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1; DIOCLEIN; FLAVONOID; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; VINPOCETINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYDROLYSIS; IC 50; PRIORITY JOURNAL; SAPHENOUS VEIN; VASCULAR TISSUE; VASODILATATION;

ANIMALS; CATTLE; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; ENDOTHELIUM, VASCULAR; FLAVANONES; HUMANS; ISOENZYMES; PHOSPHODIESTERASE INHIBITORS; SAPHENOUS VEIN; VASODILATION;

EID: 70349106337     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.008     Document Type: Article

References (54)

1. Ahn H.S., Foster M., Foster C., Sybertz E., and Wells J.N. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem. Pharmacol. 38 (1989) 3331-3339
2. Ahn H.S., Bercovici A., Boykow G., Bronnenkant A., Chackalamannil S., Chow J., Cleven R., Cook J., Czarniecki M., Domalski C., Fawzi A., Gree M., Gundes A., Ho G., Laudicina M., Lindo N., Ma K., Manna M., McKittrick B., Mirzai B., Nechuta T., Neustadt B., Puchalski C., Pula K., Silverman L., Smith E., Stamford A., Tedesco R.P., Tsai H., Tulshian D., Vaccaro H., Watkins R.W., Weng X., Witkowski J.T., Xia Y., and Zhang H. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity. J. Med. Chem. 40 (1997) 2196-2210
3. Almeida A.P., Cortes S.F., Ferreira A.J., and Lemos V.S. Increase on the coronary flow induced by dioclein in isolated rat heart. Life Sci. 70 (2002) 1121-1128
4. Alvarez E., Campos-Toimil M., Justiniano-Basaran H., Lugnier C., and Orallo F. Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta. Br. J. Pharmacol. 147 (2006) 269-280
5. Beavo J.A. Cyclic nucleotides phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75 (1995) 725-748
6. Bender A.T. Calmodulin-stimulate cyclic nucleotide phosphodiesterases. In: Beavo J.A., Francis S.H., and Houslay M.D. (Eds). Cyclic Nucleotide in Health and Disease (2006), CRC Press Boca Raton, FL 35-54
7. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 (2006) 488-520
8. Cortes S.F., Rezende B.A., Corriu C., Medeiros I.A., Teixeira M.M., Lopes J.M., and Lemos V.S. Pharmacological evidence for the activation of potassium channels as the mechanism involved in the hypotensive and vasorelaxant effect of dioclein in rat small resistance arteries. Br. J. Pharmacol. 133 (2001) 849-858
9. Eckly A.E., and Lugnier C. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br. J. Pharmacol. 113 (1994) 445-450
10. Favot L., Keravis T., Holl V., Le Bec A., and Lugnier C. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb. Haemost. 90 (2003) 334-343
11. Fitzpatrick D.F., Hirschfield S.L., and Coffey R.G. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am. J. Physiol. 65 (1993) 774-778
12. Follénius A., and Gérard D. Fluorescence investigations of calmodulin hydrophobic sites. Biochem. Biophys. Res. Commun. 119 (1984) 1154-1160
13. Francis S.H., and Corbin J.D. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit. Rev. Clin. Lab. Sci. 36 (1999) 275-328
14. Guzik T.J., West N.E.J., Pillai R., Taggart D.P., and Channon K.M. Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. Hypertension 39 (2002) 1088-1094
15. Herrera M.D., Zarzuelo A., Jiménez J., Marhuenda E., and Duarte J. Effects of flavonoids on rat aortic smooth muscle contractility: structure-activity relationships. Gen. Pharmacol. 27 (1996) 273-277
16. Hertog M.G.L., Feskens E.J.M., Hollman P.H.C., Katan M.B., and Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342 (1993) 1007-1011
17. Jeon Y.H., Heo Y.-S., Kim C.M., Hyun Y.-L., Lee T.G., Ro S., and Cho J.M. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell. Mol. Life Sci. 62 (2005) 1198-1220
18. Kameni-Tcheudji J.F., Lebeau L., Virmaux N., Maftei C.G., Cote R.H., Lugnier C., and Schultz P. Molecular organisation of bovine rod cGMP-phosphodiesterase 6. J. Mol. Biol. 310 (2001) 781-791
19. Keravis T., and Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily and smooth muscle signaling. In: Savineau J.P. (Ed). New Frontiers in Smooth Muscle Biology and Physiology, Transworld Research Network, Kerala (2007) 269-289
20. Keravis T., Silva A.P., Favot L., and Lugnier C. Endothelial PDEs and angiogenesis. In: Beavo J., Francis S., and Houslay M. (Eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease (2006), CRC Press, Boca Raton 417-439
21. Keravis T., Thaseldar-Roumie R., and Lugnier C. Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol. Biol. 307 (2005) 63-74
22. Knekt P., Jarvinen R., Reunanen A., and Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. Br. Med. J. 312 (1996) 478-481
23. Ko W.C., Shih C.M., Lai Y.H., Chen J.H., and Huang H.L. Inhibitory effects of flavonoids on phosphodiesterases isozymes from guinea pig and their structure-activity relationships. Biochem. Pharmacol. 68 (2004) 2087-2094
24. Komas N., Lugnier C., and Stoclet J.-C. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br. J. Pharmacol. 104 (1991) 495-503
25. Kruuse C., Rybalkin S.D., Khurana T.S., Jansen-Olesen I., Olesen J., and Edvinsson L. The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation. Eur. J. Pharmacol. 420 (2001) 55-65
26. Lemos V.S., Freitas M.R., Muller B., Lino Y.D., and Cortes S.F. Dioclein, a new nitric oxide- and endothelium-dependent vasodilator flavonoid. Eur. J. Pharmacol. 386 (1999) 41-46
27. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109 (2006) 366-398
28. Lugnier C., and Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur. Heart J. 14 (1993) 141-148
29. Lugnier C., Schoeffter P., Le Bec A., Strouthou E., and Stoclet J.-C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35 (1986) 1743-1751
30. Luscher T.F., Diederich D., Siebenmann R., Lehmann K., Stulz P., Segesser L.V., Yang Z.H., Turina M., Gradel E., and Weber E. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass graft. N. Engl. J. Med. 319 (1988) 462-467
31. Maurice D.H., Palmer D., Tilley D.G., Dunkerley H.A., Netherton S.J., Raymond D.R., Elbatarny H.S., and Jimmo S.L. Cyclic nucleotide phosphodiesterases activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 64 (2003) 533-546
32. Middleton Jr. E., Kandaswami C., and Theoharides T.C. The effect of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 52 (2000) 673-751
33. Muldoon M.F., and Kritchevsky S.B. Flavonoids and heart disease. Br. Med. J. 312 (1996) 458-459
34. Nichols M.R., and Morimoto B.H. Differential inhibition of multiple cAMP phosphodiesterases isozymes by isoflavones and tyrphostins. Mol. Pharmacol. 57 (2000) 738-745
35. 2+ sources. Naunyn. Schmiedebergs Arch. Pharmacol. 363 (2001) 612-619
36. Orallo F., Alvarez E., Basaran H., and Lugnier C. Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase inhibitory effects of hesperetin and hesperidin. Naunyn. Schmiedebergs Arch. Pharmacol. 370 (2004) 452-463
37. Orallo F., Camina M., Alvarez E., Basaran H., and Lugnier C. Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of citrus-fruits flavonoid (+/-)-naringenin. Planta Med. 71 (2005) 99-107
38. Pauvert O., Lugnier C., Keravis T., Marthan R., Rousseau E., and Savineau J.P. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Br. J. Pharmacol. 139 (2003) 513-522
39. Rybalkin S.D., Bornfeldt K.E., Sonnenburg W.K., Rybalkina I.G., Kwak K.S., Hanson K., Krebs E.G., and Beavo J.A. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J. Clin. Invest. 100 (1997) 2611-2621
40. Rybalkin S.D., Rybalkina I., Beavo J.A., and Bornfeldt K.E. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ. Res. 90 (2002) 151-157
41. Rybalkin S.D., Yan C., Bornfeldt K.E., and Beavo J.A. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 93 (2003) 280-291
42. Schoeffter P., Lugnier C., Demesy-Waeldele F., and Stoclet J.-C. Role of cyclic AMP- and cyclic-GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta: a study with selective inhibitors. Biochem. Pharmacol. 36 (1987) 3965-3972
43. Shapira O.M., Xu A., Aldea G.S., Vita J.A., Shemin R.J., and Keaney Jr. J.F. Enhanced nitric oxide-mediated vascular relaxation in radial artery compared with internal mammary artery or saphenous vein. Circulation 100 (1999) II322-II327
44. Sogo N., Campanella C., Webb D.J., and Megson I.L. S-nitrosothiols cause prolonged nitric-oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br. J. Pharmacol. 131 (2000) 1236-1244
45. Souness J.E., Brazdil R., Diocee B.K., and Jordan R. Role of selective cyclic GMP phosphodiesterases inhibition in the myorelaxant actions of M&B 22, 948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br. J. Pharmacol. 98 (1989) 725-734
46. Spearing P., Majetich G., and Bhattacharyya J. Synthesis of dioclein, a flavanone from the roots of Dioclea grandifora. J. Nat. Prod. 60 (1997) 399-400
47. Stoclet J.-C., Keravis T., Komas N., and Lugnier C. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases. Exp. Opin. Investig. Drugs 4 (1995) 1081-1100
48. Truss M.C., Uckert S., Stief C.G., Kuczyk M., Schulz-Knappe P., Forssmann W.G., and Jonas U. Effects of various phosphodiesterase inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro. Neurourol. Urodyn. 15 (1996) 59-70
49. Vila J.M., Martinez-Leon J.B., Medina P., Segarra G., Ballester R.M., Otero E., and Lluch S. U-46619-induced potentiation of noradrenergic constriction in the human saphenous vein: antagonism by thromboxane receptor blockade. Cardiovasc. Res. 52 (2001) 462-467
50. Wallis R.M., Corbin J.D., Francis S.H., and Ellis P. Tissue distribution of phosphodiesterases families and the effects of sildenafil on tissue cyclic nucleotides, platelet functions and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. 83 (1999) 3C-12C
51. Wu S.N., Li H.F., and Chiang H.T. Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells. Biochem. Pharmacol. 61 (2001) 877-892
52. Yan C., Zhao A.Z., Bentley J.K., and Beavo J.A. The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J. Biol. Chem. 271 (1996) 25699-25706
53. Yontem O., Sahilli M., Karasu C., Ozcelikay A.T., Altan V.M., and Ari N. Troglitazone has no effect on K(ATP) channel opener induced-relaxations in rat aorta and in human saphenous veins from patients with type 2 diabetes. Life Sci. 68 (2000) 557-568
54. Yu J., Wolda S.L., Frazier A.L., Florio V.A., Martins T.J., Snyder P.B., Harris E.A., McCaw K.N., Farrell C.A., Steiner B., Bentley J.K., Beavo J.A., Ferguson K., and Gelinas R. Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1. Cell. Signal. 9 (1997) 519-529